<img alt="" height="1" width="1" />Ocera Therapeutics Demonstrates Proof of Principle for the Use of AST-120 in ...PR Newswire (press release)Irritable bowel syndrome (IBS) is a chronic intermittent condition, affecting ~12% of the population, in which patients experience abdominal pain or ...<nobr>and more »</nobr> |